Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Benzbromarone→

Benzbromarone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
3562-84-3
Molecular formula
C17H12Br2O3
Molecular weight
424.1 g/mol
Drug class
Uricosuric agentnon-purine xanthine oxidase inhibitor
Mechanism of action
Lowers serum urate through uricosuric activity by reducing renal tubular urate reabsorption; published pharmacology also describes non-purine xanthine oxidase inhibition. The relative contribution of each action depends on the source and product.
Indications / reported uses
  • Treatment of chronic hyperuricaemia and gout in selected patients where authorised, generally when first-line urate-lowering therapy is unsuitable or ineffective. It is not for treatment of an acute gout attack. Use is limited in many jurisdictions because of serious hepatotoxicity, including reports of fatal liver injury.

Sources: NIDDK LiverTox — Benzbromarone · Bahrain Ministry of Health drug information — Benzbromarone · PubChem summary (LiverTox/ChEBI records) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Benzbromarone Environmental Risk Assessment (ERA) (the Benzbromarone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.